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ABSTRACT 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
adalimumab prevents the loss of visual acuity in patients with uveitis. 
STUDY DESIGN:  Review of three English language primary studies published between 2013-
2016. 
DATA SOURCES:  Two randomized controlled phase 3 trials and one retrospective study were 
found using PubMed.  The RCT’s compared treatment with adalimumab to placebo in patients 
with noninfectious uveitis, while the retrospective study solely assessed outcomes in patients with 
noninfectious uveitis receiving adalimumab treatment. 
OUTCOMES MEASURED: For the two RCT’s, the clinical outcome of time to treatment failure 
due to worsening visual acuity was measured by calculating logMAR from the Early Treatment 
Diabetic Retinopathy Study (EDTRS) chart in each eye. For these two studies visual Functioning 
questionnaires (VFQ-25) were also administered.  In the retrospective study visual acuity was 
measured using Snellen charts. 
RESULTS:  The randomized controlled phase 3 trials found a statistically significant decrease in 
treatment failure due to a worsening of visual acuity in the patients treated with adalimumab over 
placebo.  In Jaffe et al. the mean change in best corrected visual acuity (BCVA) was significantly 
less for the adalimumab group, however, in Nguyen et al the difference was not statistically 
significant.  The VFQ-25 was in favor of the adalimumab group in both studies but was not 
significant in Nguyen et al.  A larger number of serious adverse events were associated with the 
adalimumab group compared to placebo, but no new safety issues were identified. The 
retrospective study also showed improvement in visual outcomes for noninfectious uveitis patients 
treated with adalimumab. 
CONCLUSION: Adalimumab can help prevent loss of visual acuity in adult patients with 
noninfectious intermediate, posterior or panuveitis.   
KEYWORDS: Adalimumab, uveitis 
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INTRODUCTION  
Uveitis is an inflammatory condition of the uveal tract.  The uvea is the middle layer of 
the eye and uveitis is classified based on the location of the inflammation within the uveal tract.  
Anterior uveitis includes inflammation of the iris and ciliary body and is the most common form 
of the condition.  Intermediate uveitis involves the vitreous and peripheral retina, while posterior 
uveitis manifests as inflammation in the choroid or retina.  Inflammation throughout all of these 
structures is termed panuveitis.  These four classifications of uveitis can also be subtyped into 
more specific diagnoses if the inflammation is localized to a specific portion of either the 
anterior, intermediate or posterior segment of the uvea. 
The development of uveitis is influenced by systemic inflammatory diseases, infections, 
trauma and genetics.1  A prompt diagnosis of uveitis and referral to an ophthalmologist is 
essential as the complications of the inflammatory process can deteriorate one’s vision.1  
Complications from uveitis include blindness, glaucoma, macular edema, adhesions, band 
keratopathy and optic nerve damage.2  Up to 40 percent of cases are due to an underlying 
systemic inflammatory disease, which are often treated with systemic corticosteroids.1  
Corticosteroids are also the current mainstay of treatment for non-infectious uveitis and chronic 
therapy can further contribute to complications like cataracts, glaucoma, osteoporosis, metabolic 
syndrome and immunosuppression.1  Uveitis currently accounts for 10-15 percent of cases of 
blindness in Western countries and can be prevented by early diagnosis and adequate treatment.3 
The presenting symptoms of uveitis vary based on the location of the inflammation, 
contributing to its difficult diagnosis.  Patients are more likely to present to the emergency 
department with significant pain and injection in anterior uveitis, while posterior and 
intermediate uveitis is more commonly painless with vision changes.1  Uveitis is estimated to 
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account for 5 million health care visits per year, with an annual incidence of 17-52 cases per 
100,000 persons.4  Racial predispositions to uveitis are related to the autoimmune diseases that 
are more prevalent in certain ethnic populations.1  The underlying systemic inflammatory 
conditions associated with uveitis like systemic lupus erythematous and inflammatory bowel 
disease are often debilitating diseases themselves and are associated with significant medical 
costs.  An additional diagnosis of uveitis has been estimated to cost $935 to $1,738 per month 
depending upon the treatments pursued.4  
The current treatment regimen for acute non-infectious uveitis is to provide 
anticholinergic eye drops to induce cycloplegia and mydriasis to help reduce pain. Topical or 
systemic corticosteroids are also administered to reduce inflammation.1  Approximately half of 
patients with uveitis will not have remission of symptoms with corticosteroid use alone.1 Once a 
patient begins to require more than 10mg/day of prednisone, an immunosuppressive drug is 
considered.4  Antimetabolites and cytotoxic agents are used help reduce inflammation and 
preserve vison, however, long-term treatment with methotrexate, cyclosporine and azathioprine 
have complications like renal insufficiency, hypertension, thrombocytopenia and hepatic 
toxicity.4  Adalimumab has been shown to reduce the inflammation associated with uveitis and 
can be an effective treatment, limiting the amount of corticosteroid use and preventing the visual 
deterioration associated with uveitis as well as the complications from glucocorticoid use. 
OBJECTIVE:  The objective of this systematic review is to determine whether or not 
adalimumab prevents the loss of visual acuity in patients with uveitis. 
METHODS: The population of the studies used in this review included patients with active or 
inactive noninfectious uveitis and their ages ranged from 4-81 years old.  Two randomized 
controlled trials and one retrospective study were used in this review.  In the RCT’s, patients 
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were given either a subcutaneous injection of placebo or 80mg of adalimumab at baseline, 
followed by 40 mg every two weeks.  A burst of prednisone was also administered at baseline 
and then tapered over two weeks.  Treatment was continued for 80 weeks or until the patient 
experienced treatment failure.  The retrospective study by Dobner et al. evaluated patients that 
were given 40 mg of adalimumab every two weeks with an average follow up of 87.9 weeks.  
Measurements of the patients change in visual acuity over the course of treatment was the 
clinical outcome looked at for selection of these studies. 
 The keywords used for research were “adalimumab” and “uveitis”, in the databases 
PubMed and Cochrane Systematic Review.  The included articles were published in English and 
in peer reviewed journals between 2013-2016.  The studies selected for this review were chosen 
based on their evaluation of patient oriented outcomes (POEMs).  Inclusion criteria were studies 
that were published within 10 years and at least two of them were RCT’s.  Exclusion criteria 
included studies that did not evaluate POEMs or evaluated patients with infectious causes of 
uveitis.   Statistics reported in this review include p values, hazard ratios, mean change and 
numbers needed to harm. 
Table 1. Demographics and Characteristics of included studies 
Study Type #pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Dobner, 
2013 (4) 
Retrospective 60 4-71 Patients with uveitis 
refractory to other 
immunosuppressive 
treatment 
Infectious uveitis 13 Adalimumab 40mg 
every 2 weeks  
Jaffe, 
2016 (5) 
RCT 217 18-81  18 years or older 
with active 
noninfectious 
intermediate, 
posterior, or 
panuveitic uveitis.  
despite the use of 
Prednisone. No 
previous, active or 
latent TB. 
Isolated anterior uveitis.  
Confirmed or suspected 
infectious uveitis.  
Contraindication pupil dilation.  
Corneal or lens opacity that 
impaired visualization of the 
fundus. Previous exposure to 
anti-TNF therapy or any 
biologic therapy with a 
potential therapeutic impact on 
17 Adalimumab 80mg at 
baseline and 40mg 
doses every 2 weeks.  
60mg/d prednisone 
burst followed by 
taper.  
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OUTCOMES MEASURED:  Jaffe et al. and Nguyen et al. evaluated the efficacy of adalimumab 
over placebo based on comparison of time to treatment failure.  Treatment failure was 
determined when changes in the eye indicative of uveitic flare were noticed, or a decrease in the 
patients best corrected visual acuity by 15 or more letters on the Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart.  Study visits were done at baseline and weeks one, four, six, 
eight and every four weeks thereafter.  Visits were continued until treatment failure was 
determined or until 80 weeks was reached.  The primary clinical outcome being assessed in this 
review is visual acuity, which in the RCT’s was calculated using the logarithm of minimum 
angle of resolution (logMAR) of each eye.  Visual functioning questionnaires (VFQ-25) were 
also administered at these study visits to further compare patient outcomes in placebo versus the 
treatment group.  The VFQ-25 provides a detailed assessment of a patients perceived visual 
quality and evaluation of ocular pain.  The questionnaire consists of a VFQ-25 composite score, 
VFQ-25 distance vision sub-score, change in VFQ-25 near vision sub-score, and change in VFQ-
non-infectioius uveitis.  Using 
>1 immunosuppressive therapy 
(not including corticosteroids) 
within the last 28 days prior to 
baseline visit.  
 Nguyen, 
2016 (6) 
RCT 227 18-75 18 years or older 
with inactive 
noninfectious 
intermediate, 
posterior, or 
panuveitic uveitis. 
Inactive uveitis for 
at least 28 days 
before the baseline 
visit. Use of 10-35 
mg/d PO 
Prednisone.  
Documented history 
of at least 1 disease 
flare within 18 
months of the 
screening visit.  No 
previous or active 
TB.  
 
 
Same exclusion criteria as 
Jaffe et al. 
18 Adalimumab 80 mg at 
baseline and 40 mg 
doses every 2 weeks.  
10-35mg/d PO 
Prednisone at baseline. 
Followed by a taper 
starting at week 2. 
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25 ocular pain sub-score.  Jaffe et al. and Nguyen et al. also monitored for adverse events at each 
study visit, starting from the first administration of treatment and until 70 days after the last dose. 
In the retrospective study, Dobner et al. evaluated the effectiveness of adalimumab by 
reviewing the outcomes of patients at multiple institutions treated with adalimumab for 
noninfectious uveitis.  Improvement of uveitis was determined by an enhanced visual acuity of 
two or more lines on Snellen chart, a decrease in inflammatory markers, macular edema and 
uveitic flares or the prednisone dose the patient was previously on could be reduced to less than 
10 mg.  At least one of these criteria had to improve, while none of the others could worsen to 
determine the treatment effective. 
RESULTS:  Jaffe et al. is a phase 3 trial undertaken in 18 countries from 2010 through 2014.  
The study analyzed effectiveness of adalimumab in adult patients that were 18-81 years old and 
had active noninfectious intermediate uveitis, posterior uveitis or panuveitis.  The patients chosen 
had active infections despite the use of prednisone 10-60 mg per day and further inclusion and 
exclusion criteria is available in Table 1.  Active infection was recognized based on the National 
Eye Institute criteria and the Standardization of Uveitis Nomenclature Working Group.    
Patients were randomly assigned to receive adalimumab (80mg at baseline and 40mg every two 
weeks) or placebo and all patients were given a prednisone burst of 60mg per day followed by a 
taper, in which all had discontinued prednisone by 15 weeks.  The intention to treat analyses 
included 217 of the 223 patients randomly assigned (110 in adalimumab group and 107 in 
placebo) because six patients were omitted due to poor compliance with treatment. 
 In this systematic review the outcome being assessed from Jaffe et al. is change in visual 
acuity.  The efficacy of adalimumab in this study was determined by time to treatment failure 
and the adalimumab group had a significantly lower incidence of treatment failure due to a 
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decrease in best corrected visual acuity.  When comparing treatment failure due to a worsening 
of best corrected visual acuity (BCVA), a hazard ratio of 0.56 was calculated with a 95% CI 
(0.32-0.98) and P=0.04.  This represents that at any time during the study, half as many patients 
that were receiving adalimumab experienced treatment failure due to worsening vision than in 
the placebo group.  In Jaffe et al. the mean change in BCVA using logMAR was also calculated 
comparing the treatment and placebo groups per eye (Table 2).  The data collected represents the 
change from the BCVA before week 6 to the state of vision at the final visit.  The mean between 
group difference was -0.07 with a 95% CI (-0.11 to -0.02) and a p value of 0.003.  The mean 
between group difference of -0.07 represents a significantly smaller change in logMAR, 
demonstrating significantly more stable vision for the patients receiving adalimumab over 
placebo.  The VFQ-25 filled out by the patients favored the adalimumab group in the composite 
and all sub-score categories except the change in distance vision sub-score. 
 Throughout the Jaffe et al. study, there were six serious adverse events in the placebo 
group and 18 serious events in the adalimumab group.  Injection site reactions and allergic 
reactions were the most common adverse events, therefore, calculations were made regarding the 
incidence of serious adverse events (Table 3).  The calculated numbers needed to harm (NNH) 
for the intervention group is 24 which means that for every 24 patients treated with adalimumab, 
one more patient will experience a serious adverse event.  Some of the serious adverse events 
found in the adalimumab group included various infections, lupus and cancer.  One death was 
reported in the adalimumab group due to end stage chronic renal disease but was judged by the 
investigators to be unrelated to the intervention.   
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Table 2. Mean change in best corrected visual acuity for Jaffe et al. 
 Placebo group 
(N=107) 
Adalimumab group 
(N=110) 
Mean Between Group 
Difference (95% CI) 
P value 
 Number of 
patients 
Value 
(logMAR) 
Number of 
patients 
Value 
(logMAR) 
-0.07 (-0.11 to -0.02) 0.003 
Left eye 103 0.12 101 0.07   
Right eye 103 0.13 101 0.04   
 
Table 3. Calculations for harm from Jaffe et al. 
Control Event Rate 
(CER) 
Experimental Event Rate 
(EER) 
Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
NNH 
12% 16% 33% 4% 24 
 
Nguyen et al. is another phase 3 trial that was conducted at 62 study sites in 21 countries.  
The primary outcome measured in this double blinded, randomized, placebo controlled trial was 
to assess time to treatment failure in patients with inactive noninfectious uveitis.  Patients were 
either given a baseline loading dose of adalimumab 80mg followed by 40mg every two weeks or 
placebo.  Trial participants were also given 10-35 mg/d of oral prednisone at baseline and 
underwent a steroid taper starting at week two, in which all participants had completed by week 
19.  The main inclusion criteria stated patients must be 18 years of age or older with inactive 
noninfectious intermediate, posterior or panuveitis.  Inactivity was required for 28 days prior to 
the baseline visit and patients must have been using 10-35mg/d of prednisone to maintain 
inactivity.  Disease inactivity was based on the absence of inflammation and criteria from the 
Standardization of Uveitis Nomenclature. Further inclusion and exclusion criteria is available in 
Table 1. The intention to treat population included 226 patients, 111 in placebo and 115 in the 
treatment group. 
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 In the Nguyen et al. study the adalimumab group had significant less treatment failure 
compared to placebo and the greatest between group difference was treatment failure caused by a 
decrease in visual acuity (21% in the placebo group and 9% in the adalimumab group).  When 
comparing treatment failure due to a worsening of visual acuity, a HR of 0.33 was calculated 
with a 95% CI of 0.16-0.70 and a p value of 0.002.  This calculation states that one third as many 
of the adalimumab treated patients at any given time had treatment failure caused by worsening 
vison when compared to the placebo group.  This is an equivalent reduction in risk of 67 percent.  
The change in BCVA was also calculated for each eye and compared between groups.  The 
results favored the adalimumab group but was not statistically significant.  All of the VFQ-25 
were in favor of adalimumab except the near vision subset, but these differences between groups 
were also not significant. 
 Out of the 111 patients in the intention to treat population of the placebo group, 95 
completed the study.  Sixteen of the participants discontinued the study, seven of which were due 
to adverse events, three were lost to follow up, three withdrew because of lack of efficacy and 
three for other reasons.  In the adalimumab intention to treat population, 101 completed the study 
and 10 discontinued due to adverse events, two withdrew and two discontinued for other reasons.  
The occurrence of adverse and serious adverse event was similar between groups.  Calculations 
were made using the incidence of serious adverse events in treatment groups, with the 
adalimumab group reporting 13 serious adverse events and placebo reporting 10.  The NNH for 
adalimumab is 34 which means for every 34 patients given this intervention, one more patient 
would experience a serious adverse event (Table 5).  One malignancy of squamous cell 
carcinoma was reported in the adalimumab group.  There were four cases of latent tuberculosis, 
one of which was in the placebo group and the remaining three in the adalimumab patients.  One 
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death was reported in the adalimumab population due to aortic dissection and cardiac tamponade 
but was determined to not be related to the intervention.   
Table 4. Mean change in BCVA for Nguyen et al.  
 Placebo group 
N=111 
Adalimumab group 
N=115 
 
Mean 
difference 
(95% CI) 
P value 
 Number of 
patients 
Value 
(logMar) 
Number of 
patients 
Value 
(logMAR) 
-0.04 0.096 
Left eye 110 0.06 115 0.01   
Right eye 110 0.02 115 -0.01   
 
Table 5. Calculations for harm from Nguyen et al. 
CER EER RRI ARI NNH 
8.8% 11.7% 33% 2.9% 34 
 
In the retrospective study by Dobner et al., 60 patients receiving adalimumab treatment 
for various forms of noninfectious uveitis were identified from tertiary care centers in Vienna, 
Munster and Heidelberg.  All of the patients had received prior immunosuppressive treatment 
without improvement, which included etanercept and infliximab.  A majority of the patients 
evaluated had active anterior uveitis and systemic disease.  All of the patients in this study were 
receiving adalimumab 40mg every other week.  Fifty nine percent of the patients had 
improvement of their visual acuity, 36 percent had stable vison, while 5 percent experienced 
worsening vision.  At the last follow up visit 47 out of the 60 patients were will still receiving 
adalimumab treatment.  Eight of the patients discontinued because of inefficacy, two 
discontinued treatment because of liver enzyme elevation, one because of furunculosis, one 
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patient became pregnant, and one death due to a heart attack which was determined to not be 
related to the treatment. 
Table 6. Changes in visual acuity in patients receiving adalimumab from Dobner et al. 
 
 
DISCUSSION:  Prior to the two RCT’s discussed in this systematic review, there has been a lack 
of controlled studies on the efficacy of immunomodulatory drugs for the treatment of 
noninfectious uveitis.5,6 The added benefits of these studies included the diverse types of uveitis 
in the population as well as evaluating the ability of adalimumab to prevent uveitic flare while 
tapering patients off glucocorticoids.  The rapid discontinuation of glucocorticoid therapy in 
these studies was a limitation, because in clinical practice patients often take glucocorticoids as 
needed to help control symptoms.5  
Indication of adalimumab treatment has been evaluated and proven effective in various 
other inflammatory diseases, such as rheumatoid arthritis, psoriasis, hidradenitis suppurativa, 
ankylosisng spondylitis, Crohn’s disease, ulcerative colitis and juvenile idiopathic arthritis.7  No 
new precautions for adalimumab treatment were noted in these studies on noninfectious 
uveitis.5,6  Following the publication of the RCT’s included in this systematic review, FDA 
approval of adalimumab for the treatment of noninfectious intermediate, posterior and panuveitis 
in adults was granted.7  Black box warnings for adalimumab treatment include the risk of serious 
infections, however, most patients who developed life threatening infections were concomitantly 
Change in visual acuity Number of patients Percent % 
Improvement 35 59 
Stable 21 36 
Worsening 3 5 
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taking other immunosuppressive treatment.7  The warning recommends testing patients for latent 
TB infection and to closely monitor patients for signs of opportunistic infection throughout 
treatment.7  Increased risk of lymphoma and other malignancies is also included in the warning 
but states that it is currently unclear if the risk is associated solely with adalimumab or 
adalimumab in combination with other immunosuppressive treatment.7  Other risks associated 
with adalimumab include reactivation of hepatitis B in chronic carriers, rare cases of new onset 
or reactivation of neurologic disorders, infrequent cases of pancytopenia have been reported and 
rarely the development of a lupus like syndrome.7  Data suggests adalimumab crosses the 
placenta but there are no known impacts on the fetus with in utero exposure or through breast 
feeding.7  
CONCLUSION:  The result of this systematic review of the literature shows that adalimumab can 
help prevent the loss of visual acuity in adult patients, specifically with noninfectious intermediate, 
posterior or panuveitis.5,6 Both the RCT’s demonstrated statistically significant reduction in 
treatment failure due to worsening BCVA.5,6 No new safety concerns were identified for 
adalimumab treatment compared to its indication in other disease, however, patient risk factors 
need to be considered prior to initiating adalimumab treatment. An open-label extension study is 
being done for long-term safety studies in patients with noninfectious uveitis receiving 
adalimumab.5,6 A limitation of the studies was the wide variety of uveitis diagnoses as this 
impaired the ability to evaluate the efficacy in specific conditions.  These studies controlled for 
the location and activity of uveitis but further research could involve studies that analyze the 
efficacy of treatment for specific causes of uveitis.  Currently adalimumab is the only FDA 
approved non-glucocorticoid therapy for noninfectious uveitis and, therefore, further study can be 
done to compare the efficacy of adalimumab and other immunomodulatory agents. 
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